Details

Autor(en) / Beteiligte

• Adames, Angela
• O’Brien, Diana Roth
• Kelly, Alison R.
• Saltz, Leonard B.
• Garcia-Aguilar, Julio
• Zinovoy, Melissa
• Williams, Vonetta
• Wu, Abraham
• Reyngold, Marsha
• Hajj, Carla
• Crane, Christopher
• Cercek, Andrea
• Smith, J. Joshua
• Markova, Alina
• Cuaron, John
• McCann, Patrick
• Romesser, Paul B.

Titel

Penile-scrotal erythrodysesthesia among rectal cancer patients receiving fluoropyrimidine-based chemoradiation: a case report series

Ist Teil von

• International journal of colorectal disease, 2024-05, Vol.39 (1), p.75, Article 75

Ort / Verlag

Berlin/Heidelberg: Springer Berlin Heidelberg

Erscheinungsjahr

2024

Quelle

SpringerLink

Beschreibungen/Notizen

• Background Palmar-plantar erythrodysesthesia (PPE) is a slowly developing cutaneous reaction commonly experienced by patients treated with fluoropyrimidines. While erythrodysesthesia normally presents in a palmar-plantar distribution, it can also present with genital involvement, but this presentation is likely underreported and incorrectly attributed to an acute reaction from radiation therapy. This article aims to define erythrodysesthesia of the penis and scrotum as a rare but significant side effect of capecitabine. Case presentation We identified five cases of moderate to severe penis and scrotal erythrodysesthesia over a 2-year period at a large tertiary cancer center, representing an estimated incidence of 3.6% among male patients with rectal cancer who were treated with fluoropyrimidine-based chemoradiation within our institution. Conclusions Improved understanding of erythrodysesthesia involving the penis and scrotum can facilitate early identification and treatment of symptoms, and possibly prevent the discontinuation or delay of cancer treatment in patients treated with capecitabine and similar drugs. These clinical advances would improve and prolong patient quality of life during cancer treatment and prevent complications that result in hospitalization.